Navigation Links
Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
Date:9/11/2007

Generic Erosion of Zocor and Lipitor Will Cause Market Share of Statins to Drop Nearly 40% by 2016, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).

The new Pharmacor report Peripheral Arterial Disease finds that Genzyme's HIF-1 alpha therapy for PAD patients with intermittent claudication, which could reach the market as early as 2010, will garner sales of $1.5 billion in 2016 in the world's major pharmaceutical markets. Experts are optimistic about the market entry of novel angiogenic therapies, which act by generating new blood vessels in the legs and are the first agents to be developed as disease- modifying therapies for PAD. Although numerous studies will be required to establish the efficacy and safety of angiogenic products, physicians are hopeful these pioneering, PAD-specific therapies will be effective in treating the intermittent claudication and critical limb ischemia patient segments.

The report also finds that although statins will continue to dominate the PAD prescription landscape, the U.S. patent expiries of Merck's Zocor in 2006 and Pfizer's Lipitor in 2010 will cause total statin market share to drop from 58% in 2006 to 21% in 2016. The U.S. patent expiry of Zocor will prompt a rapid and extensive shift in prescribing to generic equivalents from 2007 onward as third-party payers remove the brand from formularies.

"Patient-share growth will be fastest for generic Zocor, which will overtake Lipitor for prescriptions in the majority of newly diagnosed PAD patients who may be unable to afford the high co-payments associated with Lipitor," said Mary Argent-Katwala, Ph.D., analyst at Decision Resources. "The decline in statin market share will then accelerate from 2011 to 2016 after the widespread patent expiry of Lipitor."

To listen to an interview with Dr. Argent-Katwala regarding the peripheral arterial disease drug market, please visit the Find Out More section of the Decision Resources home page on September 24, 2007, at http://www.DecisionResources.com.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
2. High-Fidelity PCR with a Novel Polymerase Mixture
3. Challenge the Performance of Your Hot-Start PCRs with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System
4. Combine High Yield, Great Accuracy and the Prevention of Carry-over Contamination by Using the Novel Expand High FidelityPLUS PCR System
5. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
6. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
9. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Life-sciences conference to feature novel research with clinical potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):